Skip to main content
About Us
Overview
History
Management
Board of Directors
Partnering
Our Culture
Contact
R & D
Telomerase
Imetelstat
Publications
Pipeline
R & D Pipeline
For Patients
Clinical Trials
IMerge Phase 3
IMpactMF
IMProveMF
IMPress
TELOMERE
Hematologic Malignancies
Expanded Access Policy
Careers
Opportunities
Investors
Investors
Press Releases
Events
Stock Information
Corporate Governance
SEC Filings
Analyst Coverage
FAQs
Publications
Analyst Coverage
Home
Open
About Us
Overview
History
Management
Board of Directors
Partnering
Our Culture
Contact
Open
R & D
Telomerase
Imetelstat
Publications
Open
Pipeline
R & D Pipeline
Open
For Patients
Clinical Trials
IMerge Phase 3
IMpactMF
IMproveMF
IMpress
TELOMERE
Hematologic Malignancies
Expanded Access Policy
Open
Careers
Opportunities
Open
Investors
Terms of Use
Privacy Policy
Cookie Policy
Firm
Analyst
B. Riley Securities
Kalpit Patel
H.C. Wainwright
Vernon Bernandino
Needham & Co
Gil Blum, Ph.D.
Robert W. Baird & Co.
Joel Beatty, MD
Stifel
Stephen Willey
Geron Corp is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Geron Corp's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Geron Corp or its management. Geron Corp does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.